X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (12906) 12906
Magazine Article (51) 51
Book Chapter (41) 41
Newsletter (17) 17
Dissertation (6) 6
Newspaper Article (6) 6
Book / eBook (5) 5
Web Resource (5) 5
Book Review (1) 1
Conference Proceeding (1) 1
Government Document (1) 1
Transcript (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (11488) 11488
antiviral agents - therapeutic use (8708) 8708
ribavirin - therapeutic use (7374) 7374
male (6440) 6440
female (6183) 6183
hepatitis c, chronic - drug therapy (6148) 6148
ribavirin (5756) 5756
middle aged (5373) 5373
interferon-alpha - therapeutic use (5115) 5115
adult (4820) 4820
drug therapy, combination (4540) 4540
hepatitis c (4518) 4518
gastroenterology & hepatology (4069) 4069
treatment outcome (3992) 3992
interferon (3323) 3323
hepacivirus - genetics (3283) 3283
hepatitis c virus (3248) 3248
genotype (2888) 2888
polyethylene glycols - therapeutic use (2863) 2863
recombinant proteins (2735) 2735
hepatitis c - drug therapy (2602) 2602
aged (2385) 2385
therapy (2190) 2190
infectious diseases (2035) 2035
plus ribavirin (2026) 2026
hepatitis c, chronic - virology (2022) 2022
antiviral agents - adverse effects (1996) 1996
hepatitis (1949) 1949
hepacivirus - drug effects (1927) 1927
infection (1837) 1837
antiviral agents - administration & dosage (1770) 1770
virus-infection (1733) 1733
health aspects (1710) 1710
ribavirin - administration & dosage (1708) 1708
viral load (1643) 1643
virology (1637) 1637
pharmacology & pharmacy (1520) 1520
antiviral agents (1450) 1450
hepatitis c, chronic - complications (1436) 1436
care and treatment (1426) 1426
ribavirin - adverse effects (1422) 1422
recombinant proteins - therapeutic use (1420) 1420
biological response modifiers (1401) 1401
interferon-alpha - adverse effects (1280) 1280
rna, viral - blood (1273) 1273
interferons - therapeutic use (1270) 1270
sustained virological response (1253) 1253
drug therapy (1224) 1224
hcv (1213) 1213
interferon-alpha - administration & dosage (1194) 1194
pegylated interferon (1152) 1152
retrospective studies (1144) 1144
infections (1136) 1136
liver (1133) 1133
immunology (1078) 1078
virus diseases (1073) 1073
risk factors (1060) 1060
analysis (1031) 1031
cirrhosis (1019) 1019
combination therapy (1016) 1016
viruses (1011) 1011
animals (970) 970
time factors (956) 956
antiviral agents - pharmacology (927) 927
chronic hepatitis-c (918) 918
virus (886) 886
combination (875) 875
young adult (868) 868
hepacivirus - isolation & purification (866) 866
medicine, general & internal (863) 863
adolescent (861) 861
genetic aspects (859) 859
hepatitis c - complications (858) 858
recurrence (856) 856
chronic hepatitis c (854) 854
peginterferon alpha-2a (844) 844
hiv infections - complications (834) 834
prospective studies (825) 825
sofosbuvir (823) 823
antiviral therapy (820) 820
peginterferon (817) 817
microbiology (801) 801
gastroenterology and hepatology (789) 789
interferon-alpha (774) 774
hepatitis c, chronic - genetics (762) 762
initial treatment (762) 762
patients (762) 762
hepatitis c - virology (752) 752
transplantation (735) 735
genotypes (723) 723
research (721) 721
hiv (708) 708
telaprevir (702) 702
polyethylene glycols - adverse effects (698) 698
rna (697) 697
polyethylene glycols - administration & dosage (696) 696
hepatocellular-carcinoma (690) 690
liver transplantation (690) 690
liver cirrhosis (679) 679
fibrosis (676) 676
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (12313) 12313
Spanish (194) 194
French (189) 189
German (109) 109
Chinese (103) 103
Russian (87) 87
Japanese (85) 85
Portuguese (85) 85
Polish (48) 48
Hungarian (42) 42
Korean (25) 25
Italian (24) 24
Dutch (11) 11
Czech (6) 6
Danish (6) 6
Serbian (6) 6
Croatian (5) 5
Finnish (5) 5
Hebrew (5) 5
Turkish (5) 5
Arabic (3) 3
Swedish (3) 3
Norwegian (2) 2
Icelandic (1) 1
Lithuanian (1) 1
Romanian (1) 1
Slovak (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PloS one, ISSN 1932-6203, 07/2015, Volume 10, Issue 7, p. e0133236
Serum levels of the interferon (IFN)-stimulated chemokine CXCL10 are increased during chronic HCV infection and associate with outcome of IFN-based therapy.... 
VIRUS-INFECTION | CHEMOKINES | MULTIDISCIPLINARY SCIENCES | CHRONIC HEPATITIS-C | PROTEIN-10 | GENOTYPE 1 INFECTION | PREDICTIVE-VALUE | RIBAVIRIN | INDUCTION | ASSOCIATION | SPONTANEOUS CLEARANCE | Recurrence | Interferons | Humans | Fluorenes - therapeutic use | Dipeptidyl Peptidase 4 - blood | Hepatitis C, Chronic - virology | Male | Adult | Female | Hepacivirus - physiology | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Hepacivirus - drug effects | Sofosbuvir - therapeutic use | Virus Replication - drug effects | Chemokine CXCL10 - blood | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Dipeptidyl Peptidase 4 - genetics | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - blood | Convalescence | Chemokine CXCL10 - genetics | Protein Processing, Post-Translational | Hepatitis C, Chronic - genetics | Viral Load - drug effects | Infection | Care and treatment | Analysis | Interferon | Biological response modifiers | Hepatitis C virus | Health aspects | Therapy | Laboratories | Chronic infection | Critical care | Amino acids | Infections | Ribavirin | Clinical outcomes | Proteins | Genotype & phenotype | Hepatitis | Immunology | Hepatology | Post-translation | Pretreatment | Drug dosages | Genotypes | Statistical analysis | Liver diseases | Dendritic cells | Serum levels | Studies | Infectious diseases | CXCL10 protein | Biomarkers | Chemokines | Virus Replication/drug effects | Viral Load/drug effects | Dipeptidyl Peptidase 4/blood | Dipeptidyl Peptidase 4/genetics | Chemokine CXCL10/blood | Hepatitis C, Chronic/blood | Life Sciences | Hepatitis C, Chronic/drug therapy | Hepatitis C, Chronic/virology | Hepatitis C, Chronic/genetics | Chemokine CXCL10/genetics | Benzimidazoles/therapeutic use | Hepacivirus/physiology | Fluorenes/therapeutic use | Antiviral Agents/therapeutic use | Sofosbuvir/therapeutic use | Hepacivirus/drug effects | Ribavirin/therapeutic use
Journal Article
Mayo Clinic Proceedings, ISSN 0025-6196, 2011, Volume 86, Issue 10, pp. 1009 - 1026
.... This review article is structured to discuss antiviral therapeutics on the basis of these 3 major antiviral categories, with the caveat that some drugs discussed... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | HERPES-SIMPLEX-VIRUS | TENOFOVIR DISOPROXIL FUMARATE | PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY | POSITIVE CHRONIC HEPATITIS | CHRONIC HEPATITIS-B | ALPHA-2A PLUS RIBAVIRIN | CONGO HEMORRHAGIC-FEVER | ACUTE INTERSTITIAL NEPHRITIS | RECURRENT GENITAL HERPES | HIV-INFECTED PATIENTS | Acyclovir - therapeutic use | Foscarnet - pharmacology | Hepatitis C - drug therapy | HIV Infections - epidemiology | Humans | Ganciclovir - analogs & derivatives | Interferons - therapeutic use | Oligopeptides - therapeutic use | Hepatitis - drug therapy | Valacyclovir | Adenine - therapeutic use | Lamivudine - therapeutic use | Ganciclovir - therapeutic use | Proline - pharmacology | Protease Inhibitors - therapeutic use | Guanine - therapeutic use | Oseltamivir - pharmacology | Virus Replication - drug effects | Antiviral Agents - pharmacology | Adenine - analogs & derivatives | Valganciclovir | Organophosphonates - therapeutic use | Proline - analogs & derivatives | Antiviral Agents - therapeutic use | Comorbidity | Interferons - pharmacology | Pyrimidinones - therapeutic use | Acyclovir - pharmacology | Zanamivir - therapeutic use | Herpesviridae Infections - drug therapy | Thymidine - analogs & derivatives | Valine - therapeutic use | Oligopeptides - pharmacology | Telbivudine | Ribavirin - pharmacology | Guanine - analogs & derivatives | Oseltamivir - therapeutic use | Guanine - pharmacology | Hepatitis C - epidemiology | Nucleosides - pharmacology | Ganciclovir - pharmacology | Pyrimidinones - pharmacology | Influenza, Human - drug therapy | Drug Therapy, Combination | Nucleosides - therapeutic use | Acyclovir - analogs & derivatives | Ribavirin - therapeutic use | Valine - analogs & derivatives | Zanamivir - pharmacology | Adenine - pharmacology | Proline - therapeutic use | Organophosphonates - pharmacology | Hepatitis B, Chronic - drug therapy | HIV Infections - drug therapy | Lamivudine - pharmacology | Foscarnet - therapeutic use | Valine - pharmacology | Amantadine - pharmacology | Antiviral agents | Diagnosis | Research | Drug therapy | HIV infection | Health aspects | Symposium on Antimicrobial Therapy
Journal Article
The Journal of clinical investigation, ISSN 0021-9738, 01/2011, Volume 121, Issue 1, pp. 308 - 317
...) as an important negative prognostic biomarker Given that CXCL10 mediates chemoattraction of activated lymphocytes, it is counter-intuitive that this chemokine correlates with therapeutic... 
MEDICINE, RESEARCH & EXPERIMENTAL | LIVER INFLAMMATION | GAMMA-INDUCIBLE PROTEIN-10 | VIRUS-INFECTION | DIPEPTIDYL-PEPTIDASE-IV | ANTIVIRAL THERAPY | INSULIN-RESISTANCE | IMMUNE-RESPONSES | CHRONIC HEPATITIS-C | LEVELS CORRELATE | PEGINTERFERON PLUS RIBAVIRIN | Chemokine CXCL10 - blood | Prognosis | Antiviral Agents - therapeutic use | Receptors, CXCR3 - blood | Humans | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Chemokine CXCL10 - antagonists & inhibitors | Dipeptidyl Peptidase 4 - blood | Hepatitis C, Chronic - virology | Hepatitis C, Chronic - therapy | Recombinant Proteins | Hepatitis C, Chronic - blood | Polyethylene Glycols - therapeutic use | T-Lymphocytes - virology | Treatment Failure | Hepatitis C, Chronic - immunology | Peptide Fragments - blood | Protein Array Analysis | T-Lymphocytes - immunology | Proteases | Physiological aspects | Research | Diagnosis | Hepatitis C | Drug therapy | Chemokines | Hepatitis C, Chronic/therapy | T-Lymphocytes/immunology | Polyethylene Glycols/therapeutic use | Dipeptidyl Peptidase 4/blood | Receptors, CXCR3/blood | Chemokine CXCL10/blood | T-Lymphocytes/virology | Hepatitis C, Chronic/blood | Interferon-alpha/therapeutic use | Chemokine CXCL10/antagonists & inhibitors | Life Sciences | Immunology | Antiviral Agents/therapeutic use | Hepatitis C, Chronic/immunology | Peptide Fragments/blood | Ribavirin/therapeutic use | Hepatitis C, Chronic/virology
Journal Article
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 2012, Volume 142, Issue 6, pp. 1324 - 1334.e3
With the development of effective therapies against human immunodeficiency virus (HIV), hepatitis C virus (HCV) infection has become a major cause of morbidity... 
Gastroenterology and Hepatology | Drug Interaction | HCV | Treatment | HIV | Liver Disease | ANTIRETROVIRAL THERAPY | RANDOMIZED CONTROLLED-TRIAL | HUMAN-IMMUNODEFICIENCY-VIRUS | NATURAL-HISTORY | LIVER-DISEASE | SEXUAL TRANSMISSION | HEPATITIS-C VIRUS | ALPHA-2A PLUS RIBAVIRIN | GENOTYPE 1 INFECTION | PEGYLATED INTERFERON-ALPHA-2B | GASTROENTEROLOGY & HEPATOLOGY | Recombinant Proteins - therapeutic use | Coinfection | Antiviral Agents - pharmacokinetics | HIV Infections - epidemiology | Humans | Hepatitis C, Chronic - etiology | Male | Polyethylene Glycols - therapeutic use | Oligopeptides - therapeutic use | Serine Proteinase Inhibitors - therapeutic use | Tenofovir | Deoxycytidine - therapeutic use | Drug Interactions | Homosexuality, Male | Adenine - therapeutic use | Lamivudine - therapeutic use | Anti-HIV Agents - therapeutic use | Dideoxynucleosides - therapeutic use | Hepatitis C, Chronic - epidemiology | Drug Therapy, Combination | Raltegravir Potassium | Substance Abuse, Intravenous - complications | Emtricitabine | Liver Diseases - virology | Antiviral Agents - pharmacology | Adenine - analogs & derivatives | Drug Administration Schedule | Organophosphonates - therapeutic use | Proline - analogs & derivatives | Antiviral Agents - therapeutic use | Liver Diseases - prevention & control | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Pyrrolidinones - therapeutic use | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Disease Progression | Proline - therapeutic use | HIV Infections - etiology | Liver Cirrhosis - virology | Antiviral Agents - adverse effects | HIV Infections - drug therapy | Deoxycytidine - analogs & derivatives | Antiviral agents | Medical colleges | Care and treatment | Liver diseases | Comorbidity | Drug interactions | Mortality | Development and progression | Biological response modifiers | HIV (Viruses) | Hepatitis | Protease inhibitors | Proteases | Hepatitis C virus | Hepatitis C | Health aspects | HIV infection | Index Medicus | Abridged Index Medicus
Journal Article
Annals of internal medicine, ISSN 0003-4819, 2015, Volume 162, Issue 6, pp. 407 - 419
Journal Article
PloS one, ISSN 1932-6203, 07/2015, Volume 10, Issue 7, p. e0133028
Background The efficacy of first-generation protease inhibitor based triple-therapy against hepatitis C virus (HCV) infection is limited in HIV/HCV-coinfected... 
TELAPREVIR | PHARMACOKINETICS | SOFOSBUVIR | MULTIDISCIPLINARY SCIENCES | RESISTANCE | GENOTYPE 1 INFECTION | OPEN-LABEL | RETREATMENT | HEPATITIS-C | LEDIPASVIR | TREATMENT FAILURE | Recombinant Proteins - therapeutic use | Hepatitis C, Chronic - pathology | Coinfection | Injections, Intravenous | Prospective Studies | Humans | Middle Aged | Hepatitis C, Chronic - virology | Male | RNA, Viral - blood | Polyethylene Glycols - therapeutic use | HIV - drug effects | Oligopeptides - therapeutic use | RNA, Viral - antagonists & inhibitors | HIV Infections - pathology | Patient Safety | Adult | Female | Protease Inhibitors - therapeutic use | HIV Infections - blood | Hepacivirus - drug effects | Liver Cirrhosis - drug therapy | Silymarin - therapeutic use | Drug Administration Schedule | Antiviral Agents - therapeutic use | HIV Infections - virology | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Treatment Outcome | Liver Cirrhosis - blood | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - blood | HIV - growth & development | Antiretroviral Therapy, Highly Active | Liver Cirrhosis - virology | Liver Cirrhosis - pathology | HIV Infections - drug therapy | Hepacivirus - growth & development | Viral Load - drug effects | Infection | Highly active antiretroviral therapy | Liver diseases | RNA | Protease inhibitors | Comorbidity | Proteases | Patient outcomes | Liver | Biological products industry | Interferon | Hepatitis C virus | Therapy | Intravenous administration | Viruses | Infections | Mental depression | Epidemiology | Ribavirin | Clinical outcomes | Hepatitis | Genotype & phenotype | Acquired immune deficiency syndrome--AIDS | Antiretroviral agents | Quality | Hepatology | Human immunodeficiency virus--HIV | Gastroenterology | Safety | Ribonucleic acid--RNA | Patients | Antiretroviral therapy | Virology | Infectious diseases | Hospitals | Silibinin | Fibrosis | Hepatitis C | Acquired immune deficiency syndrome | Ribonucleic acid | AIDS | HIV | Human immunodeficiency virus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2014, Volume 370, Issue 17, pp. 1604 - 1614
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2014, Volume 370, Issue 17, pp. 1594 - 1603
In this trial in previously untreated patients with HCV genotype 1 infection and no cirrhosis, high rates of sustained response were achieved with three new... 
TRIAL | MEDICINE, GENERAL & INTERNAL | PLUS SOFOSBUVIR | C VIRUS-INFECTION | GENOTYPE 1 INFECTION | DACLATASVIR | SIMEPREVIR TMC435 | HEPATITIS-C | INTERFERON-FREE | TREATMENT-NAIVE PATIENTS | PHASE 2B | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Viral Load | Young Adult | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Female | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Drug Combinations | Uracil - analogs & derivatives | Dosage and administration | Research | Drug therapy, Combination | Hepatitis C | Drug therapy | Ribavirin | Ritonavir | Body weight | Diarrhea | Infections | Nausea | Proteinase inhibitors | Pruritus | Drug resistance | Patients | Genotype & phenotype | Cirrhosis | Sleep disorders | Hepatitis | Asthenia | Hemoglobin | Interferon | Drug dosages | Genotypes
Journal Article
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 2014, Volume 147, Issue 2, pp. 359 - 365.e1
Background & Aims The interferon-free regimen of ABT-450 (a protease inhibitor), ritonavir, ombitasvir (an NS5A inhibitor), dasabuvir (a non-nucleoside... 
Gastroenterology and Hepatology | IFN | PEARL-II | Ribavirin-Free | Interferon-Free Therapy | PLUS RIBAVIRIN | ABT-450/R-OMBITASVIR | VIRUS-INFECTION | TELAPREVIR | SOFOSBUVIR | CHRONIC HEPATITIS-C | COMBINATION | TRIAL | CIRRHOSIS | BOCEPREVIR | GASTROENTEROLOGY & HEPATOLOGY | Anilides - therapeutic use | Puerto Rico | Hepatitis C - drug therapy | United States | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | RNA, Viral - blood | Viral Load | Ritonavir - adverse effects | Time Factors | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Europe | Ribavirin - therapeutic use | Uracil - therapeutic use | Genotype | Treatment Outcome | Macrocyclic Compounds - adverse effects | Biomarkers - blood | Macrocyclic Compounds - therapeutic use | Hepatitis C - diagnosis | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Hepacivirus - growth & development | Aged | Carbamates - therapeutic use | Uracil - analogs & derivatives | Medical colleges | Care and treatment | Proteases | Ritonavir | Biological products industry | Genetic aspects | Biological response modifiers | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin
Journal Article